No Data
No Data
Yifang Biotechnology (688382.SH): The new drug Garsorasib is currently undergoing CDE review and approval for market launch.
On July 18th, Gelunhui investor asked Yifang Biotechnology (688382.SH) on the investor interactive platform, "Do we need to provide additional materials for CDE drug review of the cancer drug Gercysib?" The company replied that the new drug application for Garsorasib is currently undergoing CDE review process.
Yifang Biotechnology (688382.SH): 3.45 million restricted shares will be unlocked on July 25.
On July 17th, Gelonhui reported that the total number of shares listed for Yinfa Biotech (688382.SH) is 3.45 million. The date of the stock's listing is July 25th, 2024.
Yifang Biotechnology (688382.SH): The application for new drug release is currently being pushed forward according to plan.
On June 25th, Gelunhui reported that Yifang Biotechnology (688382.SH) stated on the investor Q&A platform that in December 2023, the market launch application for Garsorasib (D-1553 tablets) was accepted by the CDE, and it was included in the priority review program in January 2024. In June 2024, the new indication for Garsorasib (D-1553 tablets) was again included in the breakthrough therapy drug program by the CDE. The application for the new drug market is currently being promoted according to plan.
An Intrinsic Calculation For InventisBio Co., Limited (SHSE:688382) Suggests It's 22% Undervalued
Yifang Biotech (688382.SH): Net loss of 83.1777 million yuan in the first quarter
Gelonghui, April 29丨Yifang Biotech (688382.SH) released its first quarter report, with operating income of 8.06 million yuan, net loss of 83.1777 million yuan, deducting non-net loss of 83.1777 million yuan, and basic earnings per share of -0.14 yuan.
Yifang Biotech (688382.SH): 2023 net profit - $284 million
On April 25, Ge Longhui (688382.SH) released its 2023 annual report. During the reporting period, the company made every effort to promote clinical research and cooperative development of major products and made important progress. In 2023, it achieved operating income of 186 million yuan, net profit attributable to shareholders of listed companies - 284 million yuan, a year-on-year loss decrease of 41.26%. The loss margin was narrower compared to the same period last year, mainly due to the increase in the company's 2023 technical licensing and technical cooperation revenue.
No Data